A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17
Cancer Trials Ireland
Cancer Trials Ireland
National Cancer Institute (NCI)
Janssen Research & Development, LLC
University of Texas Southwestern Medical Center
University of California, San Francisco
Mayo Clinic
MOMA Therapeutics
Centers for Disease Control and Prevention
Eli Lilly and Company
University of Nebraska
Masaryk Memorial Cancer Institute
National Institutes of Health Clinical Center (CC)
FindCure Biosciences (ZhongShan) Co., Ltd.
Société Algérienne de Formation et Recherche en Oncologie
University of Virginia
University Health Network, Toronto
University of California, Los Angeles
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
Memorial Sloan Kettering Cancer Center
Canadian Cancer Trials Group
Boston Scientific Corporation
Novartis
Amgen
Imperial College London
Fatih Sultan Mehmet Training and Research Hospital
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Boston Scientific Corporation
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Northwestern University
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Axonics, Inc.
Charles Drew University of Medicine and Science
Institute of Cancer Research, United Kingdom
Memorial Sloan Kettering Cancer Center
C Ray Therapeutics
University of Nebraska
Ankara City Hospital Bilkent
Xijing Hospital
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)